France: Novalpina acquires Laboratoire XO

British mid-market investment firm Novalpina has acquired French speciality pharma business Laboratoire XO. Financial terms have not been disclosed. Founded in 2015 and based in Saint-Cloud, Laboratoire XO develops prescription medicines to treat chronic diseases. Its focus is to sell and market original drug brands. The company outsources its drug production to API manufacturers and…

You must be a HMI Subscriber to view this content. Please log in or subscribe below.

Subscribe Now »